ChlamydiaNCT06428643
A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities
A study testing Chlamydia, gonorrhea, syphilis, and HIV screening in people with Chlamydia and Gonorrhea, run by Tulane University at 1 site in United States.
Trial summary
This study includes testing for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost. If positive, individual subjects will also be counseled and offered options for treatment for themselves and their sex partners that may include no cost expedited treatment and the option to be rescreened 3 months after… Read more about this study
- Who is it for?
- Ages 15 to 26 yearsHealthy volunteers can take part
- What is being tested?
- Chlamydia, gonorrhea, syphilis, and HIV screening
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,322 participants
- Where
- 1 siteUnited States
- Study dates
- 14 Aug 2025to 1 Sep 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 26 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Identifies as African American or Black
- 15-26 years of age
- Lives or spends most of their time in Orleans Parish
- Had vaginal sex at least once
- Provide a urine or vaginal swab
- Not taken azithromycin or cefixime in the last 7 days
Who cannot join
- Unwilling or unable to provide informed consent
- Unable to speak or understand English
- Previously enrolled in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Tulane University Celia Scott Weatherhead School of Public Health and Tropical Medicine
New Orleans, Louisiana, 70112
Patricia Kissinger, PhD, 504-988-7320, kissing@tulane.edu
Momi Sagoe, MPH, 504-988-1049, msagoe@tulane.edu
About this study
Official title: A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities in Black Youth Living in the Deep South
This study includes testing for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost. If positive, individual subjects will also be counseled and offered options for treatment for themselves and their sex partners that may include no cost expedited treatment and the option to be rescreened 3 months after treatment.
- Being tested
- Chlamydia, gonorrhea, syphilis, and HIV screening
- Keywords
- Screening, Expedited Treatment
- Medical subject headings
- Chlamydia Infections, Gonorrhea, Acquired Immunodeficiency Syndrome, Syphilis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chlamydia, gonorrhea, syphilis, and HIV screeningOther
Individuals aged 15-26 years old will be tested for chlamydia, gonorrhea, HIV, and syphilis at community based venues. Individuals who test positive for chlamydia and gonorrhea and their sexual partners will be offered expedited treatment at participating pharmacies. Individuals who test positive will be asked to be rescreened for Ct/GC at 3 months post treatment.
| Study group | Role | What they receive |
|---|---|---|
| Chlamydia, gonorrhea, syphilis, and HIV screening | Experimental | Community screening of individuals for chlamydia and gonorrhea is not normally done. We are testing to see if this intervention will impact the rates of chlamydia among women. Receives: Other: Chlamydia, gonorrhea, syphilis, and HIV screening |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of chlamydia in women
Primary outcome
Measured: up to 60 months
Secondary outcomes (3)
Index participant medication pickup rate
Percentage of index participants who obtain their prescribed medication from a partnering pharmacy among all index participants who report intending to pick up the medication. Medication receipt will be determined from pharmacy billing records. Rates will be calculated monthly.
Measured: up to 60 months
Partner medication pickup rate
Percentage of partners who obtain their prescribed medication from a partnering pharmacy among all partners reported as intending to pick up the medication. Medication receipt will be determined from pharmacy billing records. Rates will be calculated monthly.
Measured: 60 months
Self reported treatment of index participants and partners
Number and percentage of index participants who report that they and all applicable partner(s) received treatment. The denominator will include index participants who provide follow-up information about their own and their partner(s)' treatment status.
Measured: 60 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 May 2024
- Study start14 Aug 2025
- Primary completion1 Sep 2028 (estimated)
- Study completion1 Sep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ChlamydiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Community based screening of young men for chlamydia, gonorrhea, HIV, and syphilis. Expedited treatment for positive subjects and their sexual partners.
- Masking
- None (open label)
- Enrolment
- 2,322 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tulane University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)
- Responsible party
- Principal investigator, Patricia Kissinger, Tulane University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06428643
- Sponsor's protocol ID
- 2024-377
- Status last verified
- Sep 2026
- First submitted
- 20 May 2024
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: We will provide de-identified data to persons who submit a reasonable request with appropriate institutional approval after the primary and secondary request questions have been published.
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities in Black Youth Living in the Deep South
- ClinicalTrials.gov ID
- NCT06428643
- Acronym / sponsor ID
- 2024-377
- Keywords
- Screening, Expedited Treatment
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 2,322 participants (estimated)
- Lead sponsor
- Tulane UniversityUniversity, hospital or other
- Collaborators
- National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)
- Study start
- 14 Aug 2025 (actual)
- Primary completion
- 1 Sep 2028 (estimated)
- Study completion
- 1 Sep 2029 (estimated)
- First posted
- 24 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study includes testing for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost. If positive, individual subjects will also be counseled and offered options for treatment for themselves and their sex partners that may include no cost expedited treatment and the option to be rescreened 3 months after treatment.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Community based screening of young men for chlamydia, gonorrhea, HIV, and syphilis. Expedited treatment for positive subjects and their sexual partners.
| Arm | Type | Receives |
|---|---|---|
| Chlamydia, gonorrhea, syphilis, and HIV screening | Experimental | Other: Chlamydia, gonorrhea, syphilis, and HIV screeningCommunity screening of individuals for chlamydia and gonorrhea is not normally done. We are testing to see if this intervention will impact the rates of chlamydia among women. |
Who may qualify
- Ages
- 15 to 26 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (6 listed)
- Identifies as African American or Black
- 15-26 years of age
- Lives or spends most of their time in Orleans Parish
- Had vaginal sex at least once
- Provide a urine or vaginal swab
Key exclusion criteria (3 listed)
- Unwilling or unable to provide informed consent
- Unable to speak or understand English
- Previously enrolled in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chlamydia, gonorrhea, syphilis, and HIV screeningIndividuals aged 15-26 years old will be tested for chlamydia, gonorrhea, HIV, and syphilis at community based venues. Individuals who test positive for chlamydia and gonorrhea and their sexual partners will be offered expedited treatment at participating pharmacies. Individuals who test positive will be asked to be rescreened for Ct/GC at 3 months post treatment. | Other | Chlamydia, gonorrhea, syphilis, and HIV screening |
Primary outcome
Rate of chlamydia in women
Time frame: up to 60 months
Primary outcome
3 secondary outcomes
Index participant medication pickup rate
Time frame: up to 60 months
Partner medication pickup rate
Time frame: 60 months
Self reported treatment of index participants and partners
Time frame: 60 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2026.
- Individual participant dataSharing planned: Yes. We will provide de-identified data to persons who submit a reasonable request with appropriate institutional approval after the primary and secondary request questions have been published.
Related trials for Chlamydia
Not yet recruitingPhase 3
A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in Young African Women
Sexually Transmitted Infection (STI), Gonorrhea
Not yet recruiting
Optimizing Antibiotic Prescription in STI Clinics Using Rapid POCT
Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection
RecruitingPhase 4
Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
Gonorrhea, Chlamydia
Not yet recruiting
Improving Clinic Delivery of HIV-related Anal Health Services
HIV, Gonorrhea
Not yet recruiting
Outcomes From Point-of-Care Sexually Transmitted Infection (STI) Testing in an Urban Sexual Health Clinic: A Randomized Trial
Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Chlamydia, gonorrhea, syphilis, and HIV screening in people with Chlamydia and Gonorrhea, run by Tulane University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Patricia Kissinger, PhD (504-988-7320, kissing@tulane.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of chlamydia in women (time frame: up to 60 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.